Gastrointestinal stromal tumor

Surgical Oncology

Volumn 17, Issue 2, 2008, Pages 129-138

  Gupta, Puneet ^a   Tewari, Mallika ^a   Shukla, Hari S ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

GIST; Imatinib; KIT; Resistant GIST

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB; KIT RECEPTOR TYROSINE KINASE; NILOTINIB; PLACEBO; SUNITINIB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADVANCED CANCER; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG RESISTANCE; DRUG SAFETY; DRUG TOLERANCE; EDEMA; ENDOSCOPIC BIOPSY; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPY; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HEADACHE; HUMAN; IMMUNOHISTOLOGY; INCIDENCE; LAPAROSCOPIC SURGERY; MYALGIA; NAUSEA; NEEDLE BIOPSY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RASH; RECURRENT CANCER; REVIEW; SKIN DISCOLORATION; TREATMENT RESPONSE; X RAY;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PIPERAZINES; PROGNOSIS; PYRIMIDINES;

EID: 41949139904     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suronc.2007.12.002     Document Type: Review

References (106)

1. Van der Zwan S.M., and De Matteo R.P. Gastrointestinal stromal tumour: 5 years later. Cancer 104 (2005) 1781-1788
2. Pidhorecky I., Cheney R.T., Kraybill W.G., and Gibbs J.F. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Annals of Surgical Oncology 7 9 (2000) 705-712
3. Levy A.D., Remotti H.E., Thompson W.M., Sobin L.H., and Miettinen M. Gastrointestinal stromal tumours: radiologic feature with pathologic correlation. Radiographics 23 (2003) 283-304
4. Bucher P., Villiger P., Egger J.F., et al. Management of gastrointestinal stromal tumours: from diagnosis to treatment. Swiss Medical Weekly 134 (2004) 145-153
5. Mazur M.T., and Clark H.B. Gastric stromal tumors: reappraisal of histogenesis. American Journal of Surgical Pathology 7 (1983) 507-519
6. Novitsky Y.W., Kercher K.W., Sing R.F., et al. Long term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumours. Annals of Surgery 243 (2006) 738-747
7. Corless C.L., Fletcher J.A., and Heinrich M.C. Biology of gastrointestinal stromal tumors. Journal of Clinical Oncology 22 38 (2004) 13-3825
8. Nowain A., Bhakta H., Pais S., et al. Gastrointestinal stromal tumors: clinical profile, pathogenesis, treatment strategies and prognosis. Journal of Gastroenterology and Pathology 20 8 (2005) 18-824
9. Kindblom L.G., Remotti H.E., Aldenborg F., and Meis- Kindblom J.M. Gastrointestinal pacemaker cell tumour (GIPACT): gastrointestinal stromal tumours show phenotypic characteristics of the interstitial cells of Cajal. American Journal of Pathology 152 (1998) 1259-1269
10. Miettinen M., Majidi M., and Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GTSTs): a review. European Journal of Cancer 231 (2002) 51-58
11. Langer C., Gunawan B., Schuler P., et al. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. British Journal of Surgery 90 (2003) 332-339
12. Miettinen M., Virolainen M., and Maarit Sarlomo R. Gastrointestinal stromal tumors value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. American Journal of Surgical Pathology 19 (1995) 207-216
13. Sarlomo-Rikala M., Kovatich A.J., Barusevicius A., et al. CDI 17: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Modern Pathology 11 (1998) 728-734
14. Judson I. Gastrointestinal stromal tumour (GIST): biology and treatment. Annals of Oncology 13 Suppl. 4 (2002) 287-289
15. Gold J.S., and De Matteo R.P. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Annals of Surgery 244 2 (2006) 176-184
16. Kindblom LG. Gastrointestinal stromal tumors; diagnosis, epidemiology, prognosis. In: ASCO Annual Meeting, Chicago, 2003.
17. Thomas R.M., and Sobin L.H. Gastrointestinal cancer. Cancer 75 Suppl. 1 (1995) 154-170
18. Fletcher C.D.M., Berman J.J., Corless C., et al. Diagnosis of gastrointestinal stromal tumours: a consensus approach. Human Pathology 33 (2002) 459-465
19. Hayashi Y., Okazaki T., Yamataka A., et al. Gastrointestinal stromal tumour in a child and review of the literature. Pediatric Surgery International 21 11 (2005) 914-917
20. De Matteo R.P., Lewis J.J., Leung D., et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Annals of Surgery 231 (2000) 51-58
21. Pierie J.-P.E.N., Choudry U., Muzikansky A., et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Archives of Surgery 136 (2001) 383-389
22. Miettinen M., Majidi M., and Lasora J. Pathology and diagnostic criteria of gastrointestinal stromal tumours (GISTs): a review. European Journal of Cancer 38 (2002) S39-S51
23. Rossi C.R., Mocellin S., Mencarelli R., Foletto M., Pilati P., Nitu D., et al. Gastrointestinal strormal tumours from surgical to a molecular approach. International Journal of Cancer 107 (2003) 171-176
24. Nishida T., Hirota S., Taniguchi M., et al. Familial gastrointestinal stromal tumours with germline mutation of the KTT gene. Nature Genetics 19 (1998) 323-324
25. Chompret A., Kannengiesser C., Barrois M., et al. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology 126 (2004) 318-321
26. Fuller C.E., and Williams G.T. Gastrointestinal manifestations of type 1 neurofibromatosis (von Recklinghausen's disease). Histopathology 19 (1991) 1-11
27. Boldorini R., Tosoni A., Leutner M., et al. Multiple small intestinal stromal tumours in a patient with previously unrecognised neurofibromatosis type 1: immunohistochemical and ultrastructural evaluation. Pathology 33 (2001) 390-395
28. Carney J.A. The triad of gastric epithelioid leiomyosarcoma, pulmonary chondroma, and functioning extra-adrenal paraganglioma: a five-year review. Medicine (Baltimore) 62 (1983) 159-169
29. Emory T.S., Sobin L.H., Lukes L., et al. Prognosis of gastrointestinal smooth muscle (stromal) tuours: dependence on anatomic site. American Journal of Surgical Pathology 23 (1999) 82-87
30. Carney J.A. The triad of gastric epithelioid leiomyosarcoma, pulmonary chondroma, and functioning extra-adrenal paraganglioma: a five-year review. Medicine (Baltimore) 62 (1983) 159-169
31. Wingen C.B., Pauwels P.A., Debiec-Rychter M., van Gemert W.G., and Vos M.C. Uterine gastrointestinal stromal tumour (GIST). Gynecology Oncology 97 3 (2005) 970-972
32. Lam M.M., Corless C.L., Goldblum J.R., Heinrich M.C., Downs-Kelly E., and Rubin B.P. Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall. International Journal of Gynecology Pathology 25 3 (2006) 288-292
33. Suster S. Gastrointestinal stromal tumors. Seminars of Diagnostic Pathology 13 (1996) 297-313
34. D'Amato G., Steinert D.M., Mc Auliffe J.C., and Trent J.C. Update on biology and therapy of gastrointestinal stromal tumours. Cancer Control 12 1 (2005) 44-56
35. Nishida T., and Hirota S. Biological and clinical review of stromal tumours in the gastrointestinal tract. Histology and Histopathology 15 (2000) 1293-1301
36. Min K.W., and Leabu M. Interstitial cell of Cajal (ICC) and gastrointestinal stromal tumour (GIST): facts, speculation and myths. Journal of Cellular and Molecular Medicine 10 4 (2006) 995-1013
37. Liu F.Y., Qi J.P., Xu F.L., and Wu A.P. Clinicopathological and immunohistochemical analysis of gastrointestinal stromal tumour. World Journal of Gastroenterology 12 (2006) 4161-4165
38. Miettinen M., and Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Archiv 438 (2001) 1-12
39. Wang L., Vargas I.I., and French S.W. Cellular origin of gastrointestinal strorMal tumours. Archives of Pathology and Laboratory Medicine 124 147 (2000) 1-5
40. Chan K.H., Chan C.W., Chow w.h., Kwan W.K., Kong C.K., et al. Gastrointestinal stromal tumours in a cohort of Chinese patients in Hong Kong. World Journal of Gastroenterology 12 (2006) 2223-2228
41. Fletcher C.D., Berman J.J., Corless C., et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. International Journal of Surgical Pathology 10 (2002) 81-89
42. Chan K.H., Chan C.W., Chow W.H., et al. Gastrointestinal stromal tumours in a cohort of Chinese patients in Hong Kong. World Journal of Gastroenterology 14 14 (2006) 2223-2228
43. Dougherty M.J., Compton C., Talbert M., and Wood W.C. Sarcomas of the gastrointestinal tract. Annals of Surgery 214 (1991) 569-574
44. Franquemont D.W. Differentiation and risk assessment of gastrointestinal stromal tumors. American Journal of Clinical Pathology 103 (1995) 41-47
45. Ballarini C., Intra M., Ceretti A.P., et al. Gastrointestinal stromal tumors: a "benign" tumor with hepatic metastasis after 11 years. Tumori 84 (1998) 78-81
46. Ernst S., Hubbs A., Przygodzki R., Emory T., Sobin L., and O'Leary T. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Laboratory Investigation 78 (1998) 1633-1636
47. Taniguchi M., Nishida T., Hirota S., et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Research 59 (1999) 4297-4300
48. Lasota J., Jasinski M., Sarlomo-Rikala M., and Miettinen M. Mutations in exon 11 of c-kit occurs preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. American Journal of Pathology 154 (1999) 53-60
49. Ueyama T., Guo K.-J., Hashimoto H., et al. A clinicalpathologic and immunohistochemical study of gastrointestinal stromal tumours. Cancer 69 (1992) 947-955
50. Miettinen M., Monihan J.M., Sarlomo-Rikala, et al. Gastrointestinal stromal tumours/smooth muscle tumours/GISTs in the omentum and mesentery. A clinicopathologic and immunohistochemical study of 26 cases. American Journal of Surgical Pathology 23 (1999) 1109-1118
51. Rousset D., Agnes F., Lachaume P., et al. Molecular evolution of the genes encoding receptor tyrosine kinase with immunoglobulin like domains. Journal of Molecular Evolution 41 (1995) 421-429
52. Small D., Levenstein M., Kim M., et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and in involved in the proliferation of early progenitor/stem cells. Proceedings of National Academy of Sciences of the United States of America 91 (1994) 459-463
53. Fleischman R.A. From white spots to stem cells: the role of the kit receptor in mammalian development. Trends in Genetics 9 (1993) 285-290
54. Kluppel M., Huizinga J.D., Malysz J., et al. Developmental origin and kit-dependent development of the interstitial cells of cajal in the mammalian small intestine. Developmental Dynamics 211 (1998) 60-71
55. Heinrich M.C., Rubin B.P., Longley B.J., et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Human Pathology 33 (2002) 484-495
56. Nakahara M., Isozaki K., Hirota S., et al. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology 115 (1998) 1090-1095
57. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279 (1998) 577-580
58. Corless C.L., McGreevey L., Haley A., et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. American Journal of Pathology 160 (2002) 1567-1572
59. Rubin B.P., Singer S., Tsao C., et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Research 61 (2001) 8118-8121
60. Singer S., Rubin B.P., Lux M.L., et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. Journal of Clinical Oncology 20 (2002) 3898-3905
61. Heinrich M.C., Corless C.L., Duending A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299 (2003) 708-710
62. Miettinen M., Sarlomo-Rikala M., and Lasota J. KIT expression in angiosarcomas and fetal endothelial cells: lack of mutations of exon 11 and exon 17 of C-kit. Modern Pathology 13 (2000) 536-541
63. Yantiss R.K., Rosenberg A.E., Sarran L., et al. Multiple gastrointestinal stromal tumors in type I neurofibromatosis: a pathologic and molecular study. Modern Pathology (2004)
64. Mathews B.D., Joels C.S., Kercher K.W., et al. Gastrointestinal stromal tumors of the stomach. Minerva Chirugica 59 (2004) 219-231
65. Chak A., Canto M.I., Rosch T., and Dittler H.J. Endosonographic differentiation of benign and malignant stromal cell tumors. Gastrointestinal Endoscopy 45 (1997) 468-473
66. Sharp R.M., Ansel H.J., and Keel S.B. Best cases from the AFIP: gastrointestinal stromal tumor. Radiographics 21 (2001) 1557-1560
67. Scatarige J.C., Fishman E.K., Jones B., Cameron J.L., Sanders R.C., and Siegelman S.S. Gastric leiomyosarcoma: CT observations. Journal of Computer Assisted Tomography 9 (1985) 320-327
68. Hasegawa S., Semelka R.C., Noone T.C., et al. Gastric stromal sarcomas: correlation of MR imaging and histopathologic findings in nine patients. Radiology 208 (1998) 591-595
69. Van den Berg J.C., van Heesewijk J.P., and van Es H.W. Malignant stromal tumour of the rectum: findings at endorectal ultrasound and MRI. British Journal of Radiology 73 (2000) 1010-1012
70. Jager P.L., Gieterma J.A., and van der Graaf W.T. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nuclear Medicine Communication 25 (2004) 433-438
71. Hersh M., Choi J., Garrett C., and Clark R. Imaging gastrointestinal stromal tumours. Cancer Control 12 (2005) 111-115
72. Mathews B.D., Walsh R.M., Kercher K.W., et al. Laparoscopic vs open resection of gastric stromal tumors. Surgical Endoscopy 16 (2002) 803-807
73. Cuschieri A. Laparoscopic gastric resection. Surgical Clinics of North America 80 (2000) 1269-1284
74. Heinrich M.C., and Corless C.L. Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy. Journal of Surgical Oncology 90 (2005) 195-207
75. Demetri G.D., Benjamin R.S., Blanke C.D., et al. NCCN task force report: optimal management of patients with Gastrointestinal stromal tumors (GIST)-expansion and update of NCCN Clinical Practice Guidelines. Journal of National Comprehensive Network 2 (2004) S1-S26
76. De Matteo R.P., Heinrich M.C., El- Rifai W.M., and Demetri G. Clinical management of gastrointestinal stromal tumours: before and after STI-571. Human Pathology 33 (2002) 466-477
77. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine 2 (1996) 561-566
78. Debiec-Rychter M., Dumez H., et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to Imatinib in patients with advanced gastrointestinal stromal tumors entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. European Journal of Surgical Oncology 30 (2004) 1098-1103
79. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and Imatinib response in patients with metastatic gastrointestinal stromal tumors. Journal of Clinical Oncology 21 (2003) 4342-4349
80. Choi H. Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumour model. Current Oncology Reports 7 4 (2005) 307-311
81. Benjamin R.S., Choi H., Macapinlac H.A., et al. We should desist using RECIST, at least in GIST. Journal of Clinical Oncology 25 (2007) 1760-1764
82. Jager P.L., Gieterma J.A., and van der Graaf W.T. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nuclear Medicine Communication 25 (2004) 433-438
83. Van den Abbeele A.D., and Badawi R.D. Use of positron emission tomography in oncology and its potential role to asseses response to Imatinib mesylate therapy in gastrointestinal stromal tumours (GISTs). European Journal of Cancer 38 Suppl. 5 (2002) S60-S65
84. De Matteo R, Owzar K, Maki R, Pisters P, Blackstein M, Antonescu C, et al. Adjuvant Imatinib mesylate increases recurrence free survival in patients with completely resected localized primary gastrointestinal stromal tumour (GIST): North American Intergroup Phase III trial ACOSOG Z9001. In: Presented in ASCO-2007.
85. van Oosterom A.T., Judson I., Verweij J., et al. Safety and efficacy of Imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358 (2001) 1421-1423
86. Van Oosterom A.T., Judson I.R., Verweij J., et al. Update of phase I study of Imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. European Journal of Cancer 38 Suppl. 5 (2002) 83-87
87. Verweij P.J., Casali P.G., Zalcberg P.J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose Imatinib: randomized trial. Lancet 364 (2004) 1127-1134
88. Blanke C, Joensuu H, Demetri G, et al. Long-term follow up of advanced gastrointestinal stromal tumor (GIST) patients treated with Imatinib mesylate. In: Gastrointestinal cancers symposium, San Francisco, 2004.
89. Mudan S.S., Conlon K.C., Woodruff J.M., et al. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer 88 (2000) 66-74
90. Benjamin R.S., Rankin C., Fletcher C., et al. Phase III dose-randomized study of Imatinib mesylate (STI571) for GIST: intergroup S0033 early results (Abstract 3271). Proceedings of American Society of Clinical Oncology 22 (2003) 814
91. Le Cesne A., Perol D., Ray-Coquard I., et al. Interruption of Imatinib (IM) in GIST patients with advanced disease: updated results of the prospective French Sarcoma Group randomized phase III trial on survival and quality of life. Journal of Clinical Oncology 23 Suppl. 16 (2005) 9031
92. Chen L.L., Trent J.C., Wu E.F., et al. A missense mutation in KIT kinase domain I correlates with Imatinib resistance in gastrointestinal tumors. Cancer Research 64 (2004) 5913-5919
93. Tamborini E., Bonadiman L., Greco A., et al. A new mutation in KIT ATP pocket causes acquired resistance to Imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127 (2004) 294-299
94. Tarn C., and Godwin A.K. Molecular research directions in the management of gastrointestinal stromal tumors. Current Treatment Options in Oncology 6 6 (2005) 473-486
95. Rock E.P., Goodman V., Jiang J.X., et al. Food and drug administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 12 (2007) 107-113
96. Demitri G.D., Oosterom A.T.v., Garrett C.R., et al. Efficacy and safety of Sunitinib in patients with advanced gastrointestinal tumor after failure of Imatinib: a randomized controlled trial. Lancet 368 (2006) 1329-1338
97. Mehren M.V., Reichardt P., Casali P.G., Blay J., Debiec-Rychter M., Dumez H., et al. A phase-I study of Nilotinib alone and in combination with Imatinib in patients with Imatinib-resistant gastrointestinal stromal tumors (GIST)-study update. Journal of Clinical Oncology 25 18 Suppl. (2007) 10023
98. Bui B.N., Blay J., Duffaud F., Hermine O., and Cesne A.L. Preliminary efficacy and safety results of masitinib administered, front line in patients with advanced GIST: a phase II study. Journal of Clinical Oncology 25 18 Suppl. (2007) 10025
99. Reubi J.C., Korner M., Waser B., Mazzucchelli L., and Guillou L. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. European Journal of Nuclear Medicine and Molecular Imaging 31 6 (2004) 803-810
100. Bucher P., Taylor S., Villiger P., Morel P., and Brundler M.A. Are there any prognostic factors for small intestinal stromal tumors?. American Journal of Surgery 187 6 (2004) 761-766
101. Bucher P., Villiger P., Egger J.F., Buhler L.H., and Morel P. Management of gastrointestinal stromal tumors: from diagnosis to treatment. Swiss Medical Weekly 134 (2004) 145-153
102. Van den Abbeele A.D., and Badawi R.D. Use of positron emission tomography in oncology and its potential role to assess response to Imatinib mesylate therapy in gastrointestinal stromal tumours (GISTs). European Journal of Cancer 38 Suppl. 5 (2002) S60-S65
103. Stroobants S., Goeminne J., Seegers M., Dimitrijevic S., Dupont P., et al. 18 FDG-POSITRON emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with Imatinib mesylate (Glivec). European Journal of Cancer 30 (2003) 2012-2020
104. Shi Y., Du C., Fu H., Zhao G., and Zhou Y. The prognostic analysis of gastrointestinal stromal tumour. Journal of Clinical Oncology 25 18 Suppl. (2007) 20534
105. Demetri G.D., Benjamin R., Blanke C.D., et al. Optimal management of patients with gastrointestinal stromal tumors (GIST): expansion and update of NCCN clinical practice guidelines. Journal of Comprehensive Cancer Network 2 suppl. 1 (2004) 1-26
106. Blay J.Y., Bonvalot S., Casali P., et al. Consensus meeting for the management of gastrointestinal stromal tumors: report of the GIST consensus conference of 20-21 March 2004, under the auspices of ESMO. Annals of Oncology 16 (2005) 566-578